Department of Pharmacology, Tasly R&D Institute, Tianjin Tasly Group Co, Ltd, Pujihe East Road, No 2, BeiChen District, Tianjin 300410, China.
J Ethnopharmacol. 2011 Oct 11;137(3):1457-61. doi: 10.1016/j.jep.2011.08.035. Epub 2011 Aug 29.
Significant pharmacokinetic/pharmacodynamic (PK/PD) interactions between various herbal products and warfarin have recently been reported. The present study was conducted to determine whether Compound Danshen Dripping Pills (CDDP), a Chinese herb medicine used for the treatment of cardiovascular diseases, interacts with warfarin when administered concomitantly.
Each day for 7 days two groups of rats were treated orally with CDDP (50mg/kg and 250 mg/kg, twice daily), and the control group received similar treatment with appropriate volumes of water only. Sixty minutes after the final daily administration of CDDP or water, an aqueous solution of warfarin (0.2mg/mL) was given to each rat at a dose of 1.0mg/kg, and blood samples were collected at 0, 0.5, 1, 2, 4, 8, 12, 24, 36, and 48 h after warfarin-treatment. The concentration of warfarin in blood plasma was determined by high performance liquid chromatography (HPLC). Prothrombin time (PT) in blood plasma was measured using thromboplastin reagent.
Excellent linearity was found between 0.05 and 10 μg/mL with a lower limit of quantitation (LLOQ) of 0.05 ng/mL (r>0.999); moreover, all the validation data including accuracy and precision (intra- and inter-day), were within the required limits. No significant differences were found in PT(max) and AUC(PT0-∞) between the two CDDP-treated groups and the control. Besides, there was little alteration in any of the pharmacokinetic parameters of warfarin between the two CDDP-treated groups and the control.
The concomitant application of CDDP and warfarin did not give rise to significant effect on the pharmacodynamics of warfarin, and practically no effect on its pharmacokinetics. It was speculated that the PK/PD interactions between CDDP and warfarin was likely to be negligible as long as the patients took CDDP at a normal dose.
最近有报道称,各种草药产品与华法林之间存在显著的药代动力学/药效学(PK/PD)相互作用。本研究旨在确定复方丹参滴丸(CDDP),一种用于治疗心血管疾病的中药,与华法林同时给药时是否会发生相互作用。
每天连续 7 天,两组大鼠分别口服 CDDP(50mg/kg 和 250mg/kg,每日两次),对照组给予相同体积的水进行类似治疗。最后一次每日 CDDP 或水给药后 60 分钟,给予每只大鼠 1.0mg/kg 的华法林水溶液(0.2mg/mL),并在华法林治疗后 0、0.5、1、2、4、8、12、24、36 和 48 小时采集血样。采用高效液相色谱法(HPLC)测定血药中华法林的浓度。采用凝血酶试剂测定血药中凝血酶原时间(PT)。
在 0.05 至 10μg/mL 之间发现了良好的线性关系,定量下限(LLOQ)为 0.05ng/mL(r>0.999);此外,所有验证数据,包括准确度和精密度(日内和日间),均在要求范围内。与对照组相比,两个 CDDP 治疗组的 PT(max)和 AUC(PT0-∞)均无显著差异。此外,与对照组相比,两个 CDDP 治疗组的华法林任何药代动力学参数均无明显变化。
CDDP 与华法林同时应用对后者的药效学无显著影响,对华法林的药代动力学也无显著影响。推测只要患者以正常剂量服用 CDDP,CDDP 与华法林之间的 PK/PD 相互作用可能可以忽略不计。